Shots:

• Richter has launched Terrosa- a biosimilar to Eli Lilly’s Forsteo approved for osteoporosis in postmenopausal women and in men at high risk of fracture and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture
• Richter launched Terrosa through its affiliates in Europe following the patent expiry of the Forsteo in Aug’ 2019. The in vivo non-clinical studies and the clinical study demonstrated biosimilarity data to Forsteo
• Terrosa is a biosimilar to the biologically active fragment of the human parathyroid hormone which replaces the natural hormone thus stimulating bone formation and has received EC’s approval in Jan’2017 following CHMP’s positive opinion

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Business Review